Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018 / 임상당뇨병
Journal of Korean Diabetes
;
: 71-75, 2018.
Artigo
em Coreano
| WPRIM
| ID: wpr-726887
ABSTRACT
The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific anti-diabetic drugs over others with regard to cardiovascular disease (CVD) and mortality prevention. Recently, two novel anti-diabetic medications proved to be significantly protective against future CVD and mortality, regardless of the glycemic levels achieved in type 2 diabetic patients with pre-existing CVD. The 2018 ADA Guidelines recommend SGLT2 inhibitor and/or GLP-1 receptor agonist be used for type 2 diabetes patients with atherosclerotic CVD after metformin monotherapy failure. Considering the value of CVD protection in the management of diabetes mellitus, this minor guideline adjustment could have far-reaching implications.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Doenças Cardiovasculares
/
Mortalidade
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Transportador 2 de Glucose-Sódio
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Estilo de Vida
/
Metformina
Tipo de estudo:
Guia de Prática Clínica
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS